Evaluation of Saruparib Safety and Pharmacodynamics in Adults with Advanced Solid Malignancies

The primary objective of this clinical trial is to evaluate the **safety** and pharmacokinetics of saruparib in adults with **advanced solid malignancies**. This is clinically relevant as it aims to determine the tolerability and appropriate dosing of saruparib, which could potentially lead to new therapeutic options for patients with these types of cancers. No secondary objectives are provided in the available data.

The clinical trial involves a total of **12 participants** diagnosed with **advanced solid malignancies**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is characterized by the presence of advanced solid tumors, and no specific lifestyle considerations such as diet or physical activity were highlighted. The sponsor did not provide detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of **saruparib** in adults with **advanced solid malignancies**. This Phase 3 trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thereby minimizing bias. The trial is expected to commence recruitment on March 24, 2025, and is projected to conclude by November 19, 2026, with the overall duration spanning approximately 20 months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess the drug's efficacy, and record any adverse events. These visits are integral to ensuring participant safety and collecting data on the drug's performance. The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather concluding data on the treatment's impact.

The expected length of participant involvement is contingent upon the individual's response to the treatment and the absence of any adverse effects that may necessitate early withdrawal. Conditions that could lead to early termination from the study include significant adverse reactions, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to uphold scientific rigor and ensure the collection of reliable data, contributing to the understanding of saruparib's role in treating advanced solid malignancies.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on March 24, 2025, with an estimated completion date of November 19, 2026. Efficacy will be evaluated using specific parameters, although these are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific endpoints, are not specified in the available information. The trial's focus is on obtaining robust data to support the evaluation of the treatment's effectiveness in the targeted medical condition, which is not named in the source material. The trial's design and execution will adhere to the rigorous standards expected in Phase 3 clinical research.